227 related articles for article (PubMed ID: 31136417)
1. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
[TBL] [Abstract][Full Text] [Related]
3. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
4. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Wei XC; Zhao MF; Li X; Xiao X
Int J Antimicrob Agents; 2020 Oct; 56(4):106112. PubMed ID: 32721598
[TBL] [Abstract][Full Text] [Related]
5. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Mangal N; Hamadeh IS; Arwood MJ; Cavallari LH; Samant TS; Klinker KP; Bulitta J; Schmidt S
Clin Pharmacol Ther; 2018 Nov; 104(5):957-965. PubMed ID: 29315506
[TBL] [Abstract][Full Text] [Related]
7. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
Kadam RS; Van Den Anker JN
Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
[TBL] [Abstract][Full Text] [Related]
10. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
11. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Voriconazole Dosing Regimens Against Aspergillus Species and Candida Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on Pharmacokinetic/Pharmacodynamic Analysis.
Xie M; Jiang M; Qiu H; Rong L; Kong L
J Clin Pharmacol; 2023 Sep; 63(9):993-1001. PubMed ID: 37083934
[TBL] [Abstract][Full Text] [Related]
15. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
Wang T; Zhang T; Meng T; Li Y; Chen L; Yang Q; Dong H; Lei J; Chen L; Dong Y
J Transl Med; 2018 Jun; 16(1):157. PubMed ID: 29880050
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
Liao S; Ge T; Zhu L; Zhao Y; Yang J; Xu G
Pharmazie; 2015 May; 70(5):306-9. PubMed ID: 26062298
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.
Rudramurthy SM; Seyedmousavi S; Dhaliwal M; Chakrabarti A; Meis JF; Mouton JW
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821453
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
20. Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic-pharmacodynamic analysis of tear fluid following oral administration.
Tamura N; Okano A; Kuroda T; Niwa H; Kusano K; Matsuda Y; Fukuda K; Mita H; Nagata S
Vet Ophthalmol; 2020 Jul; 23(4):640-647. PubMed ID: 32383526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
